Home › Focal Segmental Glomerulosclerosis › Georgia
Focal Segmental Glomerulosclerosis clinical trials in Georgia
6 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in Georgia.
Cities in Georgia
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Emory Children's Center- Site Number : 8400020, Atlanta
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- Emory Children's Center, Atlanta
- Coastal Medical Research, LLC, Brunswick
- Southeast Kidney Associates - East Point, East Point
- and 1 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 17, 2026 · NCT07220083A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- Investigator Site # 1, Lawrenceville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT07268638NEPTUNE Match Study
- Emory University Hospital - Children's Hospital of Atlanta, Atlanta
Recruiting
Ages 1 to 80 · All sexes · Updated Jun 10, 2026 · NCT04571658Nephrotic Syndrome Study Network
- Emory University and Children's Healthcare of Atlanta, Atlanta
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- Emory University School of Medicine, Atlanta
RecruitingPhase 3
Ages 12 to 80 · All sexes · Updated Feb 3, 2026 · NCT05183646From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.